Drug intelligence / Profile preview

propofol + isoflurane

Development stage: Phase 3
Lead developer: AkzoNobel
Modality: Small Molecules
Administration: Intravenous, Inhalation

Overview

A combination anesthetic approach using propofol (an intravenous general anesthetic) and isoflurane (an inhaled general anesthetic) concurrently. This combination allows for reduced doses of each individual agent while maintaining effective anesthesia. The combination has been studied for its effects on endoplasmic reticulum stress and cognitive function, with research suggesting it may better protect cognitive function than either agent alone at higher doses in certain conditions.

Brand names: Forane + Diprivan
Other names: isoflurane and propofolisoflurane plus propofol

Targets

NeuraminidaseGABRR (GABA-A receptor subunit rho)ND1 (Mitochondrial electron transport chain complex I)ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on propofol + isoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + isoflurane.